Deep-pocketed investors have adopted a bullish approach towards Novo Nordisk (NYSE:NVO), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in NVO usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 9 extraordinary options activities for Novo Nordisk. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 55% leaning bullish and 44% bearish. Among these notable options, 2 are puts, totaling $97,500, and 7 are calls, amounting to $332,890.
Predicted Price Range
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $100.0 to $150.0 for Novo Nordisk during the past quarter.
Volume & Open Interest Development
In today's trading context, the average open interest for options of Novo Nordisk stands at 1988.56, with a total volume reaching 2,194.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Novo Nordisk, situated within the strike price corridor from $100.0 to $150.0, throughout the last 30 days.
Novo Nordisk Call and Put Volume: 30-Day Overview
Noteworthy Options Activity:
Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
---|
NVO | CALL | SWEEP | BULLISH | 09/20/24 | $3.75 | $3.7 | $3.7 | $140.00 | $84.3K | 8.6K | 255 |
NVO | CALL | TRADE | BULLISH | 01/16/26 | $46.0 | $45.05 | $46.0 | $100.00 | $69.0K | 770 | 16 |
NVO | CALL | TRADE | BEARISH | 01/16/26 | $28.4 | $25.35 | $26.1 | $130.00 | $54.8K | 700 | 0 |
NVO | PUT | SWEEP | BEARISH | 08/23/24 | $1.08 | $0.77 | $1.08 | $132.00 | $54.0K | 552 | 500 |
NVO | PUT | TRADE | BULLISH | 12/20/24 | $14.75 | $14.5 | $14.5 | $145.00 | $43.5K | 106 | 30 |
About Novo Nordisk
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
After a thorough review of the options trading surrounding Novo Nordisk, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
Novo Nordisk's Current Market Status
- Trading volume stands at 1,297,641, with NVO's price up by 2.03%, positioned at $137.15.
- RSI indicators show the stock to be may be approaching overbought.
- Earnings announcement expected in 77 days.
Professional Analyst Ratings for Novo Nordisk
In the last month, 2 experts released ratings on this stock with an average target price of $160.0.
- An analyst from Cantor Fitzgerald downgraded its action to Overweight with a price target of $160.
- Consistent in their evaluation, an analyst from BMO Capital keeps a Outperform rating on Novo Nordisk with a target price of $160.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Novo Nordisk options trades with real-time alerts from Benzinga Pro.
财力雄厚的投资者对诺和诺德(纽约证券交易所代码:NVO)采取了看涨态度,这是市场参与者不容忽视的。我们对本辛加公开期权记录的追踪今天揭示了这一重大举措。这些投资者的身份仍然未知,但是NVO的如此实质性的变动通常表明重大事件即将发生。
我们今天从观察中收集了这些信息,当时Benzinga的期权扫描仪重点介绍了诺和诺德的9项非同寻常的期权活动。这种活动水平与众不同。
这些重量级投资者的总体情绪存在分歧,55%的人倾向于看涨,44%的人倾向于看跌。在这些值得注意的期权中,有两个是看跌期权,总额为97,500美元,7个是看涨期权,总额为332,890美元。
预测的价格区间
分析这些合约的交易量和未平仓合约,看来大型企业一直在关注诺和诺德在过去一个季度的价格范围从100.0美元到150.0美元不等。
交易量和未平仓合约的发展
在当今的交易背景下,诺和诺德期权的平均未平仓合约为1988.56,总成交量达到2,194.00。随附的图表描绘了过去30天内Novo Nordisk高价值交易的看涨和看跌期权交易量以及未平仓合约的变化情况,行使价走势从100.0美元到150.0美元不等。
Novo Nordisk 看涨和看跌交易量:30 天概述
值得注意的期权活动:
Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
---|
NVO | CALL | SWEEP | BULLISH | 09/20/24 | $3.75 | $3.7 | $3.7 | $140.00 | $84.3K | 8.6K | 255 |
NVO | CALL | TRADE | BULLISH | 01/16/26 | $46.0 | $45.05 | $46.0 | $100.00 | $69.0K | 770 | 16 |
NVO | CALL | TRADE | BEARISH | 01/16/26 | $28.4 | $25.35 | $26.1 | $130.00 | $54.8K | 700 | 0 |
NVO | PUT | SWEEP | BEARISH | 08/23/24 | $1.08 | $0.77 | $1.08 | $132.00 | $54.0K | 552 | 500 |
NVO | PUT | TRADE | BULLISH | 12/20/24 | $14.75 | $14.5 | $14.5 | $145.00 | $43.5K | | |
关于 Novo Nordisk
诺和诺德拥有全球品牌糖尿病治疗市场约三分之一的份额,是全球领先的糖尿病护理产品提供商。该公司总部位于丹麦,生产和销售各种人用和现代胰岛素、注射型糖尿病治疗药物(如 GLP-1 疗法)、口服抗糖尿病药物和肥胖疗法。Novo还有一个生物制药板块(约占收入的10%),专门研究血友病和其他疾病的蛋白质疗法。
在对围绕Novo Nordisk的期权交易进行了全面审查之后,我们将对该公司进行更详细的审查。这包括评估其当前的市场状况和表现。
诺和诺德的当前市场状况
诺和诺德的专业分析师评级
上个月,2位专家发布了该股的评级,平均目标价为160.0美元。
期权交易带来更高的风险和潜在的回报。精明的交易者通过不断自我教育、调整策略、监控多个指标以及密切关注市场走势来管理这些风险。通过Benzinga Pro的实时提醒,随时了解Novo Nordisk的最新期权交易。